Subcutaneous vs Intramuscular TRT: Which Injection Method Delivers Better Results?

Most men starting testosterone replacement therapy are handed a syringe, told to inject into their thigh or glute, and left to figure the rest out on their own. That default route — intramuscular injection — has been the standard since the 1950s. But a different approach is gaining traction in both research and clinical practice: subcutaneous testosterone, injected into the fat tissue just under the skin using a short, thin needle.

The question is not academic. The injection route you choose affects how stable your testosterone levels stay between doses, how much pain you feel, whether you develop lumps or irritation at injection sites, and — crucially — whether you keep showing up for your injections week after week. Adherence is the factor that most determines whether TRT actually works in the real world.

This guide compares subcutaneous and intramuscular testosterone injections on the metrics that matter: pharmacokinetics, side effects, practical experience, and what 2025–2026 research says. It is informational only and should not be used to change a therapy protocol without a licensed clinician.

What Is the Anatomical Difference?

Intramuscular (IM) injection deposits testosterone ester — usually testosterone cypionate or enanthate — deep into skeletal muscle. Common IM sites are the ventrogluteal region (side of the hip), the vastus lateralis (outer thigh), and the deltoid (upper arm). The muscle is well-vascularized, which is why it was long assumed to be the ideal depot for slow-release medication. The standard needle is 1.0–1.5 inches (25–38 mm) at 22–23 gauge.

Subcutaneous (SubQ) injection deposits the same medication into the fatty tissue between the skin and the muscle layer. Common sites are the abdomen, upper outer arm, or upper outer thigh. The needle is much shorter — typically 0.5 inches (12 mm) at 27–30 gauge, the same kind used for insulin or GLP-1 injections. The medication is held in a fatty depot and absorbed into the bloodstream through capillary diffusion rather than through the denser muscular vasculature.

Absorption and Hormone Stability: What the Evidence Shows

The pharmacokinetic comparison is the most important distinction between the two routes, and it has been the subject of multiple peer-reviewed studies.

A 2022 prospective study published in the Journal of Clinical Endocrinology & Metabolism randomized men with hypogonadism to receive either subcutaneous or intramuscular testosterone cypionate for 12 weeks. The study found no statistically significant difference in trough testosterone levels, peak levels, or area-under-the-curve exposure between the two routes. Both groups maintained levels within the physiological range (approximately 400–1,000 ng/dL), and safety profiles were comparable.

Several smaller studies and real-world observational data have suggested that SubQ may produce slightly lower peak levels and slightly less dramatic peaks-and-troughs compared to IM, particularly at weekly or twice-weekly dosing schedules. The mechanism is plausible: subcutaneous fat tissue is less vascularized than muscle, which creates a marginally slower and more gradual release profile. However, the magnitude of this difference is generally modest — not large enough to be clinically meaningful for most patients with either method when dosing frequency is appropriate.

The Endocrine Society's clinical practice guidelines acknowledge both routes as acceptable for testosterone administration, and the 2023 AUA (American Urological Association) guideline on male hypogonadism notes that subcutaneous administration results in "comparable androgen levels" to intramuscular injection.

Pain, Comfort, and Quality of Life

This is where SubQ has a clear and well-documented advantage for many patients.

Intramuscular testosterone injections require longer, thicker needles to penetrate through skin and subcutaneous fat into the muscle. The larger-bore needle causes more tissue trauma, and IM injections frequently produce post-injection soreness, bruising, or a dull ache in the target muscle for 24–48 hours. Some men report difficulty self-administering IM injections into the gluteal or ventrogluteal sites because of the angle and reach required.

Subcutaneous injections use a much smaller needle. Patients consistently report less injection-site pain, less bruising, and less post-injection soreness. The injection can be administered into the abdomen with the patient sitting or standing, and the pinched-fat technique is straightforward to learn. Many men who could not tolerate weekly IM injections due to pain or bruising report comfortable daily or twice-weekly SubQ dosing on 29- or 30-gauge insulin needles.

The tradeoff: subcutaneous tissue can accumulate micro-deposits over time if injections are always given at the same spot. Rotating injection sites — much like patients on insulin do — prevents the formation of fibrotic nodules or localized irritation. Some men develop small, firm lumps under the skin that resolve over days to weeks; these are deposits of the carrier oil or localized inflammatory reactions that are generally harmless but can be cosmetically concerning.

Side Effect Profiles

Both routes carry the same systemic side-effect risk profile because the same medication enters the bloodstream in comparable amounts. Hematocrit elevation, suppression of endogenous testosterone production, potential changes in lipid panels, and other systemic effects are determined by the testosterone dose and serum concentration achieved — not the route of delivery.

Injection-site reactions differ between the two routes:

• IM: deeper muscle soreness, potential for inadvertent nerve or blood vessel contact, rare cases of injection-site oil cysts or pulmonary oil microembolism (POEM) — a condition where a small amount of carrier oil enters the bloodstream during IM injection and causes transient coughing, chest tightness, or throat irritation. POEM risk is higher with large-volume IM injections.
• SubQ: superficial skin reactions, localized itching, redness, or small subcutaneous nodules. These are typically mild and self-resolving. POEM risk is essentially eliminated with SubQ because the needle does not penetrate vascularized muscle tissue.

Dosing Frequency and Practical Considerations

Intramuscular injections are typically given every one to two weeks, depending on the prescribed dose and individual pharmacokinetics. More frequent IM injections (e.g., twice weekly) reduce peak-to-trough swings but require two needle sticks per week, which some men find burdensome.

Subcutaneous injections can flexibly be administered on any schedule — twice weekly, every other day, or even daily in divided doses. Because the needle is so small, daily SubQ administration is feasible and tolerable in a way that daily IM simply is not. Many clinicians who prescribe SubQ testosterone recommend at least twice-weekly dosing to keep levels stable, though some patients split into three or four micro-doses per week.

Volume limitations: subcutaneous tissue can only comfortably accommodate a limited volume per injection. Most clinicians recommend keeping single SubQ injections under 0.5–1.0 mL. If a prescribed testosterone dose requires a larger volume, it must either be divided across multiple injection sites or the dosing frequency must be increased (which many patients prefer anyway, because it further smooths out hormone levels).

Who Is Each Method Best Suited For?

Consideration	Intramuscular (IM)	Subcutaneous (SubQ)
Needle comfort	Longer, thicker needle; moderate discomfort	Short, thin needle (27–30 ga); minimal pain
Self-administration ease	Moderate; gluteal sites difficult for self-injection	High; abdomen/thigh easily reachable
Dosing frequency	Weekly to biweekly	Twice weekly to daily
Hormone stability	Good at weekly+ dosing; more peaks at biweekly	Very good; smaller doses, more frequent = smoother curve
POEM risk	Low but real	Negligible
Site rotation needed	Between 2–3 sites (gluteal, thigh, deltoid)	Across abdomen/thigh regions to prevent nodules
Volume per injection	Up to 2–3 mL	0.5–1.0 mL recommended
Body fat considerations	Effective regardless of body fat	Very lean individuals may have limited SubQ tissue

What Do Urologists and Endocrinologists Actually Prefer?

There is no consensus guideline that mandates one route over the other. Many clinicians still default to IM out of tradition — it is what they were trained on, and the dosing schedule (weekly or biweekly) requires fewer office check-ins about self-administration. However, the proportion of providers who actively recommend or prescribe SubQ has grown substantially in recent years, driven by patient comfort reports, the ease of self-administration, and the growing clinical evidence base.

In telehealth TRT clinics and concierge hormone practices, SubQ is increasingly the default starting protocol — particularly for patients who express needle anxiety, who report poor tolerability of IM injections, or who want more granular control over their dosing schedule.

Switching Between IM and SubQ

If you are currently on IM testosterone and considering a switch to SubQ — or vice versa — the dose itself does not necessarily change. The same weekly milligram quantity of testosterone cypionate or enanthate can typically be split across more frequent SubQ administrations. Your prescribing clinician should:

• Keep the total weekly testosterone dose the same when switching routes
• Adjust the injection frequency (usually to at least twice weekly for SubQ)
• Recheck bloodwork — total testosterone, free testosterone, estradiol, hematocrit, and PSA — at the trough (just before the next injection) after 4–6 weeks on the new route to confirm that levels remain in range
• Monitor for injection-site reactions in the first few weeks after the switch

Because absorption kinetics differ slightly between routes, some patients require a small dose adjustment. This is normal and is why follow-up bloodwork is essential.

Bottom Line

Neither route is definitively superior for every patient. Intramuscular injection remains the established standard with decades of safety data and is ideal for men who tolerate it well and prefer a simple weekly or biweekly schedule. Subcutaneous injection offers comparable hormone levels with less needle pain, easier self-administration, smoother dosing flexibility, and essentially eliminated POEM risk.

The right choice depends on your comfort with needles, your ability to self-inject, your sensitivity to peaks and troughs, and your clinician's experience and preference. A conversation with your prescribing doctor — not with a forum post — is the best way to decide which route fits your therapy plan.